Delving into the Latest Updates on Xylitol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

D-Xylitol, XyliStrip, Xylitol (JP17/NF)

+ [2]

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic DiseaseMouth and Tooth DiseasesOtorhinolaryngologic Diseases

Active Indication

Diabetes MellitusXerostomiaOtitis Media

Inactive Indication

Acute otitis mediaHeart Failure

Originator Organization

Otsuka Pharmaceutical Factory, Inc.

Active Organization

The Children's Hospital Corp.

Otsuka Pharmaceutical Factory, Inc.

Rapid Dose Therapeutics Corp.

+ [1]

Inactive Organization

CoreQuest, Switzerland

Drug Highest PhaseApproved

First Approval Date

Japan (17 Feb 1970),

Diabetes Mellitus

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC5H12O5

InChIKeyHEBKCHPVOIAQTA-UHFFFAOYSA-N

CAS Registry87-99-0

This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients. A total of 99 patients who meet eligibility criteria will be randomized 1:1:1 to one of two xylitol doses or placebo arm. All arms will receive an identical capsule dosing for four weeks. Microbiome assessment and C. difficile testing will be performed at baseline, week 4, 8, 26, and 52.

Start Date01 Jan 2025

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

CTRI/2024/08/072642

/ Not yet recruitingPhase 3IIT

Comparative Evaluation of Two Different Formulations of Xylitol on Streptococcus mutans and Candida albicans in Children with Early Childhood Caries: A Randomized Controlled Trial - NIL

Start Date28 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Xylitol

Login to view more data

100 Translational Medicine associated with Xylitol

Login to view more data

100 Patents (Medical) associated with Xylitol

Login to view more data

15,253

Literatures (Medical) associated with Xylitol

01 Jul 2025·Fluid Phase Equilibria

Solubility of xylitol in mixtures of water and methanol or ethanol: Experimental measurements and thermodynamic modeling

Author: Galvao, Alessandro C. ; Scatolin, Rafael L. P. ; Robazza, Weber S. ; Arce, Pedro F. ; Gomes, Matheus V. ; Schwerz, Henrique I.

Xylitol is a sugar alc. classified as a prominent building block in the chem. industry.Besides, it is an important component in the food and pharmaceutical industries as an alternative to sucrose.The separation and purification of this chem. depend on exptl. and theor. information about solid-liquid equilibrium as a function of temperature, pressure, and compositionTherefore, this work aims to collect exptl. data on the solubility of xylitol in hydroalcoholic solutions of methanol or ethanol for the whole range of composition of the binary liquid mixture in the range between 293.2 K to 323.2 K.The data indicates that methanol is more capable than ethanol in interacting with xylitol.Moreover, the solubility of xylitol is directly proportional to temperature and the proportion of water in the solutionBinary interaction parameters were successfully optimized for the PC-SAFT and CPA equations of state, as well as for the NRTL activity coefficient model.Addnl., the solubility behavior was predicted using the modified UNIFAC and ASOG Gibbs energy models.

01 Jun 2025·Separation and Purification Technology

New family of type V natural hydrophobic deep eutectic solvents based on thymol-acetamide/acetanilide: Characteristics, intermolecular interactions and applications in liquid–liquid extraction

Author: Ebrahimi, Nosaibah ; Rafati, Solmaz ; Sadeghi, Rahmat

To develop type V hydrophobic thymol-based Deep Eutectic Solvents (DESs) with low viscosity for liquid-liquid extraction, this work briefly reviews the thymol-based DESs reported in the literature, along with their various applications, and investigates the potential for DES formation between thymol and new materials.For this purpose, 39 combinations of thymol with different amino acids (5), acids (10), carbohydrates (13), amides (2), alkylammonium halides (4), and other compounds (5) were screened, resulting in the preparation of two new thymol-acetamide and thymol-acetanilide-based DESs.To identify the optimal molar ratios for DES formation, various combinations of thymol with acetamide and acetanilide were prepared, and their abilities to form stable liquids at room temperature, along with their thermal properties, were evaluated.Based on the solid-liquid equilibrium (SLE) phase diagrams, it was found that stable liquids at ambient temperature were formed within the composition ranges of x_ACM = 0.29-0.40 (2.5:1-1.5:1) for THY:ACM and x_ACN = 0.29-0.33 (2.5:1 - 2:1) for THY:ACN.The mixtures with a molar ratio 2:1 were selected for further study, and their intermol. interactions, characteristics, and applications in dye extraction were analyzed.FT-IR and NMR analyses were performed to investigate the structure and hydrogen bond formation between the DES components.Addnl., mol. dynamic (MD) simulations were conducted to examine the mol. structure and formation mechanisms of these DESs.The results indicated that hydrogen bonds are formed between the hydroxyl group (-OH) of thymol and the carbonyl group (C=O) of acetamide/acetanilide.Thermodn. models, including regular solutions, NRTL, and Wilson, were employed to correlate the SLE phase diagrams of the studied mixtures, as determined by the DSC method.The phys. properties of the prepared DESs, such as m.p., d., speed of sound, refractive index and viscosity, were measured at different temperaturesDue to their hydrophobic nature, the DESs demonstrated stability in aqueous solutions and thus can be used to extract various analytes from aqueous environments.The obtained solvents were applied for the extraction of methylene blue, methyl orange, and rhodamine B from aqueous solutions, as well as from real textile wastewater samples.Finally, to achieve optimal extraction conditions, the effects of various factors on extraction efficiency were investigated.

01 Jun 2025·Separation and Purification Technology

High-performance polyester composite nanofiltration membrane fabricated by interfacial polymerization of ribitol and trimesoyl chloride: Dye desalination performance and mechanisms

Author: Kang, Xinwei ; Xu, Jingtao ; Sun, Zhongyue ; Qiu, Hui ; Zhou, Weiwei ; Yan, Wenxin ; Wu, Daoji ; Xu, Daliang ; Chen, Feiyong ; Zhu, Xuewu

A loose nanofiltration (LNF) membrane with high permeance and excellent dye/salt selectivity is highly desirable for dye/salts recovery from textile wastewater.Herein, com. and green ribitol (RT) was employed to fabricate the LNF membrane for dye desalination.The hydroxyl in the RT reacted with acyl chloride under the catalysis of sodium hydroxide, forming a polyester film structured with microspheres, neg. charge, and hydrophilic networks.The resultant RT-M membrane possessed a smooth and thin active layer with numerous polar groups.The dye desalination performance of the RT-M membrane was tailored by controlling various IP fabrication conditions.The optimized membrane (RT-M1.0) had superior water permeance (100.3 L m^-2h^-1 bar^-1) and satisfactory CR/Na₂SO₄ selectivity (281.3).Addnl., the RT-M membrane had favorable stability and antifouling properties, demonstrating excellent potential for application in dye desalination.Therefore, a novel approach for fabricating membranes with outstanding dye desalination properties by using RT was proposed to achieve resource recycling.

17

News (Medical) associated with Xylitol

21 Nov 2024

·www.businesswire.com

Nasal Sprays Help Alleviate Nasal Congestion

AMERICAN FORK, Utah--( BUSINESS WIRE )--Today, Nathan Jones, CEO of Xlear Inc., a consumer hygiene products company, released this statement regarding the FDA’s proposal to remove popular over-the-counter decongestants, which contain the drug phenylephrine, from the market: “With the FDA concluding that this common decongestant isn’t effective, as we enter cold and flu season, and as families prepare to celebrate the holidays, many Americans need a new answer for the discomfort of sinus congestion,” Jones noted. “For people looking for help, the U.S. Centers for Disease Control (CDC) Guidance, ‘Relief for Symptoms of Colds and Coughs’, ‘instructions’ say to ‘use saline nasal spray to relieve congestion.’ i Similarly, CDC’s ‘Sinus Infection Basics’ say ‘How to Feel Better’ ‘use a . . . saline nasal spray,’” ii he pointed out. “You experience congestion because there is an irritant or pathogen in your upper airway that your body is trying to trap and wash away—your runny nose is your body flushing it out. Saline-based nasal sprays can help speed up that flushing, reduce pathogen load, and make it more effective. It’s commonsense: The faster the bad stuff is gone, the faster you feel better,” Jones added. “For congestion caused by pathogens—like colds and flus—people can enhance that effect by using a nasal spray that contains xylitol. A series of studies show xylitol (a natural sugar) deactivates and/or blocks the adhesion of many types of viruses and bacteria, to your airway cells,” iii Jones continued. Adhesion is the process by which a pathogen attaches to your tissue to initiate infection. Using a nasal spray with xylitol helps block adhesion of these pathogens. For example, a Randomized Controlled (clinical) Trial published in 2022, determined that a saline-nasal spray containing xylitol and other ingredients reduced the rate of COVID-19 infections by 62 percent above placebo. iv “Using a basic saline would be comparable to rinsing your hands with water; using a nasal spray with xylitol, like Xlear , would be comparable to washing your hands with soap. Expect more from your nasal hygiene products. Make sure they have xylitol so you can better and faster clean out the bad stuff while alleviating the congestion,” Jones added. Xlear nasal spray is a saline-based nasal spray containing xylitol. Xlear 12 Hour Nasal Decongestant is a saline-based nasal spray containing xylitol and the decongestant Oxymetazoline HCL. For more information on Xlear please visit www.xlear.com . ____________________________ i https://www.cdc.gov/antibiotic-use/media/pdfs/HCP-Relief-Colds-Cough-85by11-P.pdf ii https://www.cdc.gov/sinus-infection/about/index.html iii For example: T Kontiokari, M Uhari, M Koskela, Antiadhesive effects of xylitol on otopathogenic bacteria., Journal of Antimicrobial Chemotherapy , Volume 41, Issue 5, May 1998, Pages 563–565, https://academic.oup.com/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext - google_vignette ; Kontiokari, T., Uhari, M., & Koskela, M. (1998). Antiadhesive effects of xylitol on otopathogenic bacteria. The Journal of Antimicrobial Chemotherapy , 41 (5), 563–565, https://academic.oup.com/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext&login=false ; Jung, Kie Hoon. (2021). Antiviral Efficacy Against Virus Infections in Human-Derived Tracheal/Bronchial Epithelial Cells. Utah State University, https://xlrtmp.com/wp-content/uploads/2023/05/Antiviral-efficacy_USU2021.pdf ; Vega, J. C., et al., (2020). Iota carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. BioRxiv , https://professionals.xlear.com/portfolio/anti-adherence-of-viruses/ ; Ruiz, V., Rodríguez-Cerrato, V., Huelves, L. et al. Adherence of Streptococcus pneumoniae to Polystyrene Plates and Epithelial Cells and the Antiadhesive Potential of Albumin and Xylitol. Pediatr Res 69, 23–27, https://www.nature.com/articles/pr920116 - citeas . iv Damian Balmforth, et al., Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial., Journal of Clinical Virology, 155; 2022, https://www.sciencedirect.com/science/article/pii/S1386653222001809 .

16 Nov 2024

·www.drugs.com

Bloated After That Holiday Meal? What's Normal, What's Not

SATURDAY, Nov. 17, 2024 -- As the holidays approach, most folks are familiar with a common side effect of the overindulgence that can come with all those meals with family and friends: Bloating. Luckily, Baylor College of Medicine gastroenterologist Dr. David Szafron has some tips on what triggers bloating, what kinds of foods are big triggers for it and when you need to see a doctor. First, bloating is defined as a feeling of trapped gas in the abdomen, fullness or abdominal pressure, Szafron said. It can last from a few minutes to a few hours, depending on what triggered it. So, what are some of those triggers? "We are still learning the ways bloating can occur," Szafron said in a Baylor news release. "Some of the most common causes are from food [and how our body processes it], medications, imbalances in our gut bacteria, changes in gut motility, prior surgery, constipation and disorders of gut-brain interaction [such as increased sensitivity of the nerves in the gut]." What are the two worst offenders as far as food goes? Two major culprits can be lactose and fructose, Safron noted. "As we age, many of us lose the enzymes needed to effectively digest these carbohydrates, which can lead to bloating," he said. "Some of these are asparagus, cauliflower, garlic, onions, mushrooms, apples, cherries, mangos, peaches, pears, watermelon, chickpeas, wheat flour, most pasta, cream cheese, cow’s milk, oat milk, soy milk, beans, tofu, sausage, cashews and pistachios." Even artificial sugars such as mannitol, xylitol and sorbitol can cause bloating. While everyone experiences bloating at some point, if it happens more than once a week over the course of several months, it might be time to use a food diary to figure out which foods are giving you trouble. Often, a pattern will emerge that spots which foods you should avoid or eat in moderation, Szafron said. Beyond dietary changes, exercise and good bowel habits can also help prevent bloating. Exercise can help stimulate the bowel and ease the symptoms of bloating. When eating foods that may trigger bloating, smaller portions can also minimize bloating. If you still experience bloating and it becomes severe enough to cause weight loss, vomiting or severe pain, see your doctor promptly, Szafron said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

17 Jun 2024

·www.drugs.com

Xylitol Linked to Incident Major Adverse Cardiovascular Event Risk

MONDAY, June 17, 2024 -- Xylitol is associated with incident major adverse cardiovascular event (MACE) risk, according to a study published online June 6 in the European Heart Journal . Marco Witkowski, M.D., from the Lerner Research Institute at the Cleveland Clinic, and colleagues performed untargeted metabolomics studies on overnight fasting plasma samples in a discovery cohort of 1,157 sequential stable patients undergoing elective diagnostic cardiac evaluations. Subsequent isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses were performed on an independent validation cohort comprising 2,149 participants. The effect of xylitol on platelet responsiveness and thrombus formation in vivo was examined in complementary isolated human platelet, platelet-rich plasma, whole blood, and animal model studies. Finally, the effects of xylitol consumption were examined on platelet function in 10 healthy volunteers. The researchers found that circulating levels of a polyol tentatively assigned as xylitol were associated with incident MACE risk in the initial untargeted metabolomics study (discovery cohort). The association of xylitol with incident MACE risk was confirmed in stable isotope dilution LC-MS/MS analyses (third versus first tertile adjusted hazard ratio, 1.57). Xylitol-enhanced multiple indices of platelet reactivity and in vivo thrombosis formation at levels observed in fasting plasma were seen in complementary mechanistic studies. Xylitol-sweetened drinks markedly raised plasma levels in interventional studies, and enhanced multiple functional measures of platelet responsiveness in all individuals. "Our studies suggest that xylitol will likely confer heightened thrombosis potential in the same vulnerable patients that it is marketed towards and intended to protect," the authors write. Several authors disclosed ties to the biopharmaceutical industry; several authors are named coinventors on pending and issued patents relating to cardiovascular diagnostics and therapeutics.

AHAClinical Study

100 Deals associated with Xylitol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00061	Xylitol	A01AA	DB11195

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	Japan	Otsuka Pharmaceutical Factory, Inc.	17 Feb 1970
Xerostomia	Canada	Rapid Dose Therapeutics Corp.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Otitis Media	Phase 3	-	The Children's Hospital Corp.	-
Heart Failure	Phase 2	-	CoreQuest, Switzerland	01 Mar 2021
Acute otitis media	Phase 2	United States	The Children's Hospital Corp.	01 Feb 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2024	Not Applicable	-	-	Xylitol	dmpuefmrij(rqwrpdtacc) = etwugwerdg bnijmncgsd (nxiifwhkpf )	-	13 Oct 2024
				xylitol (Sucrose)	dmpuefmrij(rqwrpdtacc) = dvozmgrpzv bnijmncgsd (nxiifwhkpf )
Tandem Meetings ASTCT and CIBMTR2022	Not Applicable	Hematopoietic stem cell transplantation	-	Xylitol (Standard oral care bundle)	vcodbiphdd(cfuobxfkvi) = xwxfjqcxkf fzimughiqk (jkwgydymak )	-	01 Mar 2022
NCT00928135 (CTgov)	Phase 1/2	Cystic Fibrosis	63	Hypertonic saline (7% Hypertonic Saline)	rilyiclhzu(tdawgtsbgm) = ckdkrldddt juqmmgrkqj (epwmukalbk, bkagzvpftw - acgekhjrjj) View more	-	25 Jun 2021
				Xylitol (Hypertonic Xylitol)	rilyiclhzu(tdawgtsbgm) = ibesbsspnj juqmmgrkqj (epwmukalbk, wurkzfnhuz - miwmkrmmel) View more
NCT04399161 (AEXPC, CTgov)	Phase 2/3	Dental Caries	60	Chlorhexidine (Group A (Chlorhexidine Mouthrinse))	gzluklqtil(qvsdwbtpll) = qdmmjojepz kfawslwnkt (ixafkzlerj, szmopjktfs - cplybkydft) View more	-	22 Jul 2020
				Xylitol (Group B (Xylitol Mouth Rinse))	gzluklqtil(qvsdwbtpll) = iazhvairnt kfawslwnkt (ixafkzlerj, xtkxevyzby - brltbrtnsl) View more
NCT00924404 (CTgov)	Not Applicable	Chronic sinusitis	53	Xylitol (Xylitol)	ukaqyvrysx(cweithloqq) = piurzvmksr qjfcahtbpl (knvbmkdhai, yilqqqyhlu - qwiuxilrio) View more	-	09 Aug 2017
				Saline (Saline)	ukaqyvrysx(cweithloqq) = drhvvztswy qjfcahtbpl (knvbmkdhai, cuynmtmprw - luedlbcfso) View more
Pubmed	Not Applicable	Dental Caries	-	Xylitol	ypiyqgzvjs(zganxrdmlz) = oznkjazvsw agtkzvudgk (nacmjbzfah, -0.48 to 0.01) View more	Negative	15 Mar 2017
Pubmed	Not Applicable	Dental Caries mutans streptococci (MS)	477	Xylitol	oztgljuxtw(fezevaqzpp) = wulxvnxylj ajsvdleulw (tcrxxejytk, -1.34 to -0.83) View more	Positive	01 Jan 2017
				Xylitol (Fluoride varnish)	oztgljuxtw(fezevaqzpp) = cmbsubjsfk ajsvdleulw (tcrxxejytk, -2.89 to -0.84)
NCT01044030 (CTgov)	Phase 3	Acute otitis media	326	Xylitol syrup (Xylitol Syrup)	ohglaaciii(girthrlqvd) = kvhbespcoc pktnjliyqk (gzlvjazpxc, fqdbinijkv - jjzaalrmky) View more	-	20 Mar 2015
				Placebo (Placebo)	ohglaaciii(girthrlqvd) = ognhglbwey pktnjliyqk (gzlvjazpxc, svbixbymai - fufiiorxmj) View more
ARVO2014	Not Applicable	-	-	Xylitol	(tplluiqjgj) = cmicxfmrit xtwqbfrdkh (mjuwxqjwtk ) View more	-	01 Apr 2014
				No Xylitol	(tplluiqjgj) = nwabgcpoey xtwqbfrdkh (mjuwxqjwtk ) View more
NCT03229551 (Pubmed \| Laryngoscope)	Phase 2/3	-	26	Xylitol	kvjkpzaylj(gmblmppwqr) = qnxrfyaqos zqsfizlmkv (hrbqzstshk )	-	01 Nov 2004
				Saline	kvjkpzaylj(gmblmppwqr) = rmgpsykvth zqsfizlmkv (hrbqzstshk )